Dr. Xin Huang is the professor of gynecologic oncology of Sun Yat-sen University Cancer Center. Dr. Xin Huang received her Bachelor in Medicine (equivalent to MD in the US) at Sun Yat-sen University of Medical Sciences, P. R. China in 1984. She successfully completed her residency in gynecologic oncology in 1989. Following the completion of attending programs, she was promoted to be a professor in gynecologic oncology at Sun Yat-sen University Cancer Center in 1994. Her special interests include general gynecologic surgical procedures, radical pelvic surgical procedures, and chemotherapy for malignancies arising from the female reproductive tract. She is also dedicated to taking a multidisciplinary approach to provide comprehensive care that is tailored to patients with advanced and recurrent diseases. She has been an active researcher for many years, and is well published in many peer-reviewed journals.

• General gynecologic surgical procedures
• Radical pelvic surgical procedures
• Chemotherapy
• A multidisciplinary approach to individualized patient care

• Medical Education: Sun Yat-sen University of Medical Sciences (1979-1984)
• Residency: Sun Yat-sen University Cancer Center (1984-1989)
• Attending programs: Sun Yat-sen University Cancer Center (1989-1994)

• Adjuvant docetaxel and carboplatin chemotherapy administered alone or with radiotherapy in a "sandwich" protocol in patients with advanced endometrial cancer: a single-institution experience. Expert Opin Pharmacother. 2013; 14: 535-42.

• High density of IL-17-producing cells is associated with improved prognosis for advanced epithelial ovarian cancer. Cell Tissue Res. 2013; 352: 351-9.

• Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat. 2013; 12: 259-67.

• Endometrial stromal sarcoma arising from endometriosis: a clinicopathological study and literature review. Gynecol Obstet Invest. 2012; 74: 288-97.

• Neoadjuvant docetaxel combined with cisplatin and followed by radical surgery for the treatment of locally advanced (stage IB2 - IIB) cervical cancer: preliminary results of a single-institution experience. Expert Opin Pharmacother. 2011; 12: 165-73.

 

 

Last Updated on: February 2015 by International Office, Sun Yat-sen University Cancer Center